All In Biotech

Drug Trial Radar · NCT06716281

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

398

Planned (sponsor's estimate)

Start

Jan 5, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Shanghai IxCell Biotechnology Co., LTDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis. To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

Conditions

  • Knee Osteoarthritis

Interventions

  • Human umbilical cord mesenchymal stem cellsBiological

    a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL

  • PlaceboBiological

    Sodium Chloride Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. WOMAC total scoreTime frame: 48 week
  2. cartilage damageTime frame: 48 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.